Posted by Michael Wonder on 10 Nov 2017
Heron Therapeutics announces U.S. FDA approval of Cinvanti (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting
9 November 2017 - U.S. commercial launch of Cinvanti is planned for January 2018.
Heron Therapeutics today announced that the U.S. FDA has approved Cinvanti (aprepitant) injectable emulsion, for intravenous infusion. Cinvanti is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
With this approval, Heron now is the only company with approved injectable therapies that address the two primary mechanisms of CINV: Sustol, a serotonin-3 receptor antagonist, and Cinvanti, an NK1 receptor antagonist.
